A precipitous step deeper into the CDMO business
23/11/20 -"Wacker's Biosolutions business has become a partner of choice for German mRNA player CureVac. Currently, the technology transfer for the production of CureVac's COVID-19 vaccine candidate is being ..."
Pages
53
Language
English
Published on
23/11/20
You may also be interested by these reports :
29/10/26
Linde’s Q3 results were broadly in line, with adjusted EPS of US$4.59 exceeding expectations and sales beating consensus by c.2%, potentially driven ...
29/10/26
Air Liquide’s Q326 revenue rose 3% organically to €7.26bn, slightly accelerating from H1’s 2.6%. Electronics and Industrial Merchant drove growth, ...
28/10/26
Symrise delivered another solid quarter, confirming a broader, volume-led recovery, but shares fell c.9%. Following strong peer results and a recent ...
28/10/26
BASF’s Q3 2026 was driven by price. Supply disruption in the Middle East lifted upstream pricing, but volumes did not share the optimism. ...